Actym Therapeutics
PrivateLast Round
Series A
Extension
Oct 18, 2023
Total Funding Raised
$70.74M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Actym Therapeutics operates in Healthcare & Life Sciences and is based in Berkeley, California. Its latest recorded funding round was a Series A Extension round in October 2023.
Actym Therapeutics is a biotechnology company that develops innovative immunotherapy platforms aimed at overcoming the challenging tumor immune microenvironment to provide lasting benefits for cancer patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Actym Therapeutics Comparables
Compare Actym Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GenCirq, Inc. | 85% | |
| Ernest Pharmaceuticals | 84% | |
| Salspera, Inc. | 83% |
For institutional investors. Book with your work email.
Actym Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 18, 2023 | ||||
| Series A | Jun 28, 2023 | ||||
| Series A | Apr 27, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Actym Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Boehringer Ingelheim | Series A, Series A Extension |
| Korea Investment Partners | Series A |
| Boehringer Ingelheim Venture Fund | Series A Extension, Series A |
| Panacea Venture Healthcare | Series A, Series A Extension |
| Korea Investment Partners | Series A |
| Korea Investment Partners | Series A |
| Illumina Ventures | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 384% MoM, reaching 4.8K.
- Apr 27, 2020
$34M round led by Boehringer Ingelheim and Panacea Venture Healthcare.
For institutional investors. Book with your work email.
Actym Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Actym Therapeutics's valuation, stock price, and market status.
Is Actym Therapeutics a public or private company?
Actym Therapeutics is a private company.
What is the current stock price of Actym Therapeutics?
Actym Therapeutics is a private company, so its shares have no public market price. Caplight tracks Actym Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Actym Therapeutics worth (valuation)?
Valuation information for Actym Therapeutics is not publicly available.
Can I buy Actym Therapeutics stock?
Actym Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Actym Therapeutics's last funding round?
Actym Therapeutics's most recent funding round was Series A Extension on October 18, 2023.
Who are the main investors in Actym Therapeutics?
Key investors in Actym Therapeutics include Boehringer Ingelheim, Boehringer Ingelheim Venture Fund, Panacea Venture Healthcare, Illumina Ventures.
Will Actym Therapeutics IPO soon?
No public IPO plans have been announced for Actym Therapeutics.
How can I track Actym Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Actym Therapeutics's shares on secondary markets.